MedGenome vs Tempus

Tempus has a disclosed valuation of $8.1B, while MedGenome's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.3B, compared to MedGenome's $50M — a gap of $1.3B. Combined, the two companies have completed 5 known funding rounds.

Tempus holds the higher Awaira Score at 84/100, compared to MedGenome's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 21-point gap that reflects meaningful differences in scale or traction.

MedGenome was founded by Sam Santhosh in 2013. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that leverages machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

MedGenome was founded first in 2013, giving it 2 years of additional market experience. Tempus was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

MedGenome has approximately 200-500 employees, while Tempus has approximately 2500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, MedGenome and Tempus are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.